Chiun Hsu

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim et al. · JAMA Oncology · 2020 · 1.2K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi et al. · Journal of Clinical Oncology · 2017 · 471 citations

Pharmacy, Oncology, Pharmacotherapy +17

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial

Chiun Hsu, Chao A. Hsiung, Ih‐Jen Su et al. · Hepatology · 2008 · 306 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study

Chiun Hsu, Hsiao‐Hui Tsou, Shyh-Jer Lin et al. · Hepatology · 2013 · 275 citations · Full text

Medicine, Hematology, Oncology +10